NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Nurix Therapeutics, Inc.
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026
$24.93+0.51 (+2.09%)
Close on Oct 19, 2026
- Market cap
- $2.90B
- P/E (TTM)
- 10.8
- Dividend yield
- 0.00%
Nurix Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q4 23 | TTM Q4 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration revenue | $36.77M | $41.78M | $53.98M | $53.69M | $58.38M | $56.42M | $54.55M | $56.99M | $38.63M | 100.0% | -37.0% |
| License revenue | – | – | $30.00M | – | – | – | $0 | $20.00M | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Nurix Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.